Vertex Pharmaceuticals (Canada) Inc.
Vertex Pharmaceuticals (Canada) Inc. has met with MPs 6 times since January 2024, reaching 6 MPs across 2 parties. Most recent contact: June 4, 2026.
What they're asking for
In the registry's own words. Descriptions are only filed for meetings since mid-2024.
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
June 4, 2026 · Juanita Nathan · Liberal · Health; Industry; Intellectual Property; Science and Technology; Budget
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
March 24, 2026 · Dan Mazier · Conservative · Health; Industry; Intellectual Property; Science and Technology; Budget
Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
November 19, 2025 · Michael Coteau · Liberal · Health; Industry; Budget
Full meeting log
6 MP-directed communications since January 2024, from the Registry of Lobbyists.
| Date | MP |
|---|---|
| 2026-06-04 | Juanita Nathan · Liberal |
| 2026-03-24 | Dan Mazier · Conservative |
| 2026-03-10 | Tom Kmiec · Conservative |
| 2026-03-10 | Salma Zahid · Liberal |
| 2026-03-09 | Judy A. Sgro · Liberal |
| 2025-11-19 | Michael Coteau · Liberal |